ArticleClinicoEconomics and outcomes research : CEOR2025

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Bhavesh Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.